is a peptide-based therapy designed for systemic lupus erythematosus (SLE). Its mechanism of action revolves around modulating autophagy, a process involved in immune system regulation.

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...

EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.

In a new study published in Lupus Science & Medicine, researchers assessed clinical trial perceptions among a predominantly Black cohort of participants with systemic lupus erythematosus (SLE).

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of ...

Patients with Klinefelter and triple X syndromes show an increased prevalence of SLE and Sjögren disease, likely due to the ...

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...

found that 27% of individuals with systemic lupus erythematosus (SLE) had hearing loss. This was significantly higher than in the control group. Participants with SLE showed worse hearing at lower ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

Apoptosis and autophagy constitute the two self-destructive processes by which supernumerary, damaged or aged cells and organelles are eliminated. Beyond this homeostatic function, autophagy is ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

Since 2008, when the first EULAR recommendations for the management of systemic lupus erythematosus (SLE) were published and widely adopted,1 a series of specific recommendations on disease monitoring ...